These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 13679030)

  • 41. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
    Gambacorti C
    Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
    [No Abstract]   [Full Text] [Related]  

  • 43. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
    Kancha RK; von Bubnoff N; Miething C; Peschel C; Götze KS; Duyster J
    Haematologica; 2008 Nov; 93(11):1718-22. PubMed ID: 18728023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A myristoyl/phosphotyrosine switch regulates c-Abl.
    Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
    Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 46. [An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes].
    Von Bubnoff N; Peschel C; Duyster J
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2100-3. PubMed ID: 15455301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
    FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of tyrosine kinase inhibitor imatinib mesylate on K562 cell invasion by PTEN pathway].
    Cheng ZY; Liang WT; Yan XY; Wan JS; Bian YS; Bai P; Liang LQ; Jie JQ; Li AM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1129-32. PubMed ID: 23127398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
    Corbin AS; Buchdunger E; Pascal F; Druker BJ
    J Biol Chem; 2002 Aug; 277(35):32214-9. PubMed ID: 12077114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
    Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
    Atwell S; Adams JM; Badger J; Buchanan MD; Feil IK; Froning KJ; Gao X; Hendle J; Keegan K; Leon BC; Müller-Dieckmann HJ; Nienaber VL; Noland BW; Post K; Rajashankar KR; Ramos A; Russell M; Burley SK; Buchanan SG
    J Biol Chem; 2004 Dec; 279(53):55827-32. PubMed ID: 15507431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Src-like inactive conformation in the abl tyrosine kinase domain.
    Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
    PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
    Ross DM; Hughes TP
    Br J Cancer; 2004 Jan; 90(1):12-9. PubMed ID: 14710199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571.
    Böhmer FD; Karagyozov L; Uecker A; Serve H; Botzki A; Mahboobi S; Dove S
    J Biol Chem; 2003 Feb; 278(7):5148-55. PubMed ID: 12435730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.